Hugo Geerts

Certara (United States) — United States

Computer Science · Physical Sciences

39h-index5.7kcitations215works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(48), Alzheimer's disease research and treatments(47), Neuroscience and Neuropharmacology Research(32), Cholinesterase and Neurodegenerative Diseases(31), Receptor Mechanisms and Signaling(21)

Publications215 total

Interactions of Therapeutic Antibodies With Presynaptically‐Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte‐Carlo Simulation Study
CPT Pharmacometrics & Systems Pharmacology·2025Open Access
IUPHAR review: Computational Psychiatry 2.0. A new tool for supporting combination therapy of psychopharmacology with neuromodulation in schizophrenia
Pharmacological Research·2025Open Access
QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease
2025
Quantitative Systems Pharmacology Development and Application in Neuroscience
Handbook of experimental pharmacology·2025· 4 cited
Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease
Clinical Pharmacology & Therapeutics·2024· 9 citedOpen Access
Exploring biological response profiles to amyloid antibodies in clinical practice using Quantitative Systems Pharmacology
Alzheimer s & Dementia·2024· 1 citedOpen Access
Towards predicting individual cognitive trajectories in AD using Quantitative Systems Pharmacology
Alzheimer s & Dementia·2024Open Access
Poor in vivo transduction of myocardium by lentiviral vectors is likely caused by a post-entry block of transduction
Cardiovascular Research·2024Open Access
Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice
Alzheimer s & Dementia Translational Research & Clinical Interventions·2024· 7 citedOpen Access
Exploring treatment guidelines for amyloid therapies in Alzheimer’s Disease Using Predictive Quantitative System Pharmacology Modeling
Alzheimer s & Dementia·2023· 2 citedOpen Access
Mechanistic modeling of tau biomarkers for amyloid load. A Quantitative Systems Pharmacology study of amyloid‐tau interaction.
Alzheimer s & Dementia·2023Open Access
Editorial: Innovative pharmacometric approaches to inform drug development and clinical use
Frontiers in Pharmacology·2023Open Access
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model
Scientific Reports·2023· 22 citedOpen Access
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases
Journal of Pharmacokinetics and Pharmacodynamics·2023· 6 cited
Learning from anti‐tau antibody clinical trials using computer simulation of spatial tau propagation
Alzheimer s & Dementia·2023Open Access
Clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration: a quantitative systems pharmacology model analysis
Research Square (Research Square)·2023Open Access
Mechanism-guided analysis of avalglucosidase alfa efficacy on key biomarkers and clinical endpoints in late-onset Pompe disease patients
Molecular Genetics and Metabolism·2023
A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
CPT Pharmacometrics & Systems Pharmacology·2023· 18 citedOpen Access
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
Journal of Pharmacokinetics and Pharmacodynamics·2022· 5 cited
Hallmarks of neurodegenerative disease: A systems pharmacology perspective
CPT Pharmacometrics & Systems Pharmacology·2022· 43 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Rony Nuydens(9), Äthan Spiros(7), Chris Van den Haute(6), Kurt Spittaels(5), Fred Van Leuven(5), Patrick J. Roberts(5), Jo Van Dorpe(4), Kris Vandezande(4), M. De Brabander(4), Gwenda Dispersyn(4), Μ. Borgers(4), Jan‐Mark Geusebroek(3), A.W.M. Smeulders(3), Koen Bruynseels(3), Isabelle Laenen(3), Marc Mercken(3), Ruth J. F. Loos(3), Reena Lasrado(3), Gerd Van Den Kieboom(3), Harald Hampel(3)